Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls

被引:84
作者
Dautzenberg, Geraud [1 ]
Lijmer, Jeroen [2 ]
Beekman, Aartjan [3 ]
机构
[1] Altrecht Inst Mental Hlth Care, Dept Old Age Psychiat, Utrecht, Netherlands
[2] OLVG Hosp, Dept Psychiat, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, GGZ InGeest, Amsterdam, Netherlands
关键词
dementia; mild cognitive impairment; MoCA; old age psychiatry; spectrum-bias; validation; NORMATIVE DATA; IMPAIRMENT; DEMENTIA; VALIDATION; DEPRESSION; CRITERIA; VERSION; METAANALYSIS; SCALE; CARE;
D O I
10.1002/gps.5227
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective/methods The Montreal Cognitive Assessment (MoCA) is an increasingly used screening tool for cognitive impairment. While it has been validated in multiple settings and languages, most studies have used a biased case-control design including healthy controls as comparisons not representing a clinical setting. The purpose of the present cross-sectional study is to test the criterion validity of the MoCA for mild cognitive impairment (MCI) and mild dementia (MD) in an old age psychiatry cohort (n = 710). The reference standard consists of a multidisciplinary, consensus-based diagnosis in accordance with international criteria. As a secondary outcome, the use of healthy community older adults as additional comparisons allowed us to underscore the effects of case-control spectrum-bias. Results The criterion validity of the MoCA for cognitive impairment (MCI + MD) in a case-control design, using healthy controls, was satisfactory (area under the curve [AUC] 0.93; specificity of 73% less than 26), but declined in the cross-sectional design using referred but not cognitive impaired as comparisons (AUC 0.77; specificity of 37% less than 26). In an old age psychiatry setting, the MoCA is valuable for confirming normal cognition (greater than or equal to 26, 95% sensitivity), excluding MD (greater than or equal to 21; negative predictive value [NPV] 98%) and excluding MCI (greater than or equal to 26;NPV 94%); but not for diagnosing MD (less than 21; positive predictive value [PPV] 31%) or MCI (less than 26; PPV 33%). Conclusions This study shows that validating the MoCA using healthy controls overestimates specificity. Taking clinical and demographic characteristics into account, the MoCA is a suitable screening tool-in an old age psychiatry setting-for distinguishing between those in need of further diagnostic investigations and those who are not but not for diagnosing cognitive impairment.
引用
收藏
页码:261 / 269
页数:9
相关论文
共 47 条
[1]  
[Anonymous], J ATTEN DISORD
[2]  
[Anonymous], WORLD ALZHEIMER REPO
[3]  
[Anonymous], 2013, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD010460
[4]  
Ballard DH, 2015, COMPUT NEUROSCI-MIT, P1, DOI 10.7551/mitpress/9780262028615.001.0001
[5]   Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression - A systematic review [J].
Baune, Bernhard T. ;
Renger, Lisa .
PSYCHIATRY RESEARCH, 2014, 219 (01) :25-50
[6]   Effects of anxiety versus depression on cognition in later life [J].
Bierman, EJM ;
Comijs, HC ;
Jonker, C ;
Beekman, ATF .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 13 (08) :686-693
[7]   Meta-analysis of Cognitive Impairment in First-Episode Bipolar Disorder: Comparison With First-Episode Schizophrenia and Healthy Controls [J].
Bora, Emre ;
Pantelis, Christos .
SCHIZOPHRENIA BULLETIN, 2015, 41 (05) :1095-1104
[8]   Improving dementia care: The role of screening and detection of cognitive impairment [J].
Borson, Soo ;
Frank, Lori ;
Bayley, Peter J. ;
Boustani, Malaz ;
Dean, Marge ;
Lin, Pei-Jung ;
McCarten, J. Riley ;
Morris, John C. ;
Salmon, David P. ;
Schmitt, Frederick A. ;
Stefanacci, Richard G. ;
Mendiondo, Marta S. ;
Peschin, Susan ;
Hall, Eric J. ;
Fillit, Howard ;
Ashford, J. Wesson .
ALZHEIMERS & DEMENTIA, 2013, 9 (02) :151-159
[9]   STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies [J].
Bossuyt, Patrick M. ;
Reitsma, Johannes B. ;
Bruns, David E. ;
Gatsonis, Constantine A. ;
Glasziou, Paul P. ;
Irwig, Les ;
Lijmer, Jeroen G. ;
Moher, David ;
Rennie, Drummond ;
de Vet, Henrica C. W. ;
Kressel, Herbert Y. ;
Rifai, Nader ;
Golub, Robert M. ;
Altman, Douglas G. ;
Hooft, Lotty ;
Korevaar, Daniel A. ;
Cohen, Jeremie F. .
CLINICAL CHEMISTRY, 2015, 61 (12) :1446-1452
[10]  
BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416